Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

SAUDI PHARMACEUTICAL JOURNAL, published by Elsevier, stands as a pivotal platform for scholarly communication within the realm of pharmaceutical sciences and pharmacology. With a commendable Q2 ranking in both Pharmaceutical Science and Pharmacology for 2023, this journal reflects a strong commitment to advancing scientific understanding and innovation. Open Access since 2009, the journal ensures that cutting-edge research is readily accessible to researchers, professionals, and students around the globe, fostering collaboration and knowledge sharing. Based in the Netherlands, the journal covers a wide scope of topics, contributing to a cumulative understanding of drug development, therapeutic strategies, and pharmaceutical education. With a significant presence in Scopus rankings—#57 in Pharmaceutical Science and #116 in Pharmacology—SAUDI PHARMACEUTICAL JOURNAL is a trusted resource for high-quality research that shapes the future of pharmaceutical sciences.

Journal of Research in Pharmacy, published by Marmara University, serves as a pivotal platform for the dissemination of innovative research in the field of pharmacology and pharmaceutical sciences. With an ISSN of 2630-6344 and an E-ISSN of the same, this journal is dedicated to publishing high-quality research spanning various aspects of pharmacology, toxicology, and pharmaceutics. The journal, categorized in Q3 for both pharmacology (medical) and miscellaneous pharmacology, toxicology, and pharmaceutics in 2023, showcases the ongoing evolution of these disciplines amid growing scientific inquiry. As of now, it ranks #56/80 in general pharmacology, toxicology and pharmaceutics, spotlighting its relevance within the academic community. Although it operates under a traditional access model, the journal is committed to providing researchers, professionals, and students with a comprehensive understanding of contemporary challenges and innovations in pharmacy research. Established in 2019, it continues to foster academic dialogue and contribute significantly to the advancement of pharmacological sciences until at least 2024. For all interested in cutting-edge pharmaceutical research, this journal presents an invaluable resource from its base in Istanbul, Turkey.

RSC Medicinal Chemistry is a pivotal journal in the realm of medicinal chemistry, published by the esteemed Royal Society of Chemistry. With a focus on innovative research that intersects various disciplines such as biochemistry, drug discovery, pharmaceutical science, and organic chemistry, this journal serves as a vital resource for researchers, professionals, and students alike. Its impressive impact factor and notable rankings—positioning it within the Q1 and Q2 quartiles across critical categories—underscore its significance in advancing knowledge and fostering collaboration within the scientific community. RSC Medicinal Chemistry is dedicated to open access, ensuring that cutting-edge findings on drug design and therapeutic applications are freely available to enhance global research efforts. With a commitment to publication excellence from 2020 to 2024, it is a prominent platform where groundbreaking ideas meet practical implications, making it indispensable for anyone committed to the forefront of medicinal advances.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

Annales Pharmaceutiques Francaises, an esteemed journal published by MASSON EDITEUR, serves as a pivotal platform in the field of Pharmaceutical Science and Pharmacology. Established in 1945 and continuing through 2024, this journal showcases significant contributions to the advancement of pharmaceutical sciences, bridging the gap between research, development, and practical applications. Although it currently does not offer open access, its established reputation and Q3 ranking in both Pharmaceutical Science and Pharmacology highlight its role in disseminating impactful studies. With an ISSN of 0003-4509, the journal is indexed in Scopus, boasting a respectable percentile ranking for both domains, and remains a vital resource for researchers, professionals, and students dedicated to exploring the latest advancements in the pharmaceutical field. Based in France, at 21 Street Camille Desmoulins, Issy, 92789 Moulinais Cedex 9, it aims to foster a deeper understanding of pharmacological innovations and therapeutic agents among its diverse readership.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.